Of all the claims and fears associated with the use of artificial intelligence, its promise in the field of biotechnology is, in my opinion, most convincing. Having witnessed the prolonged and risky course of drug development from both the perspective of a provider and a patient, I foresee significant benefits afforded by the availability of A.I.
New drug development has long been slowed by the complexities of animal and/or human-based studies, including unforeseen complications. As a result, it generally takes years to bring a life-saving therapy to market, among the major reasons for its high cost. Artificial intelligence is able to identify both effective therapies and potential side-effects within a relatively short period of time, thereby improving both the efficiency and the safety of this vital process.
No doubt, there are many convincing arguments against the overuse and unmonitored application of artificial intelligence. But its value in the field of biotechnology seems to be especially promising.
